Introduction
Zika virus is an emerging mosquito-borne virus that ws first identified in Uganda in 1947 in Africa It was first confirmed in Brazil in May 2015. It has since been identified in more than 27 countries and territories in the region 1, 2 . Spread to the Americas was predicted because of the abundance of the mosquito vector, Aedes aegypti 3, 4, 5, 6 . Clinicians worldwide need to be aware of Zika virus infection owing to international travel and the presence of another potentially competent mosquito vector (Aedes albopictus) in North America and southern Europe. Some Brazilian regions experiencing outbreaks of Zika infection have reported an apparent increase in congenital microcephaly and post-infective neurological syndromes, particularly Guillain-Barré 2 .
The association of these conditions with Zika virus infection is currently unproved and is under investigation. On 1 February 2016, the World Health Organization (WHO) declared the recent cluster of microcephaly and other neurological disorders reported in Brazil, following a similar cluster in French Polynesia in 2014, a public health emergency of international concern 7 . If Zika virus infection is confirmed to cause congenital microcephaly, this could lead to a large international burden of infant neurological morbidity. Zika virus infection should be considered in people presenting with compatible symptoms who have recently returned from countries where outbreaks of the infection are occurring. This review provides up to date information on Zika virus, its evolving epidemiology, how to recognize its clinical presentation, possible complications, and how to confirm the diagnosis.
What is Zika virus?
Zika virus is an arbovirus (arthropod borne virus 
Transmission
The key Zika virus vector is thought to be the daytime biting (indoors and outdoors), urban dwelling Aedesaegypti mosquito. Evidence to support this comes from detection of the virus in wild A aegypti and by experimental transmission in rhesus monkeys [30] [31] [32] .
Following laboratory feeding of Aedes albopictus mosquitoes with Zika virus infected blood, the virus has been demonstrated in mosquito saliva, suggesting these mosquitoes may also transmit the virus 33, 34 . Presumptive sexual transmission has been reported in two cases 35, 36 .
Isolation of virus in semen 17 days after a clinical diagnosis of acute infection supports potential sexual transmission, as does the detection of Zika virus RNA in semen 62 days after the onset of symptoms 37, 38 . Zika virus was detected in approximately 3% of asymptomatic blood donors during the French Polynesian outbreak, 39 suggesting that transmission might be possible through infected blood and blood products. Evidence implies transplacental transmission and perinatal transmission during delivery, with Zika virus RNA being found in amniotic fluid 15 and in paired blood samples taken from newborn infants and mothers 40 . There is currently no evidence to support transmission via contact with saliva, urine, or respiratory droplets.
Clinical Presentation
Zika virus infections seem either to be subclinical (possibly in as many as 80% of infections) or to cause a mild illness after an incubation period of three to 12 days. Symptoms, which last for approximately two to seven days include fever, conjunctivitis, arthralgia, myalgia, and widespread rash, which may be itchy. Headache, retro-orbital pain, peripheral oedema, and gastrointestinal disturbance have also been observed 3, 41 .
Only one study has examined the proportion of infections that produce symptoms. 42 .
In addition to dengue and chikungunya, other diagnoses that should be considered include HIV seroconversion, measles, scarlet fever, rickettsial infection, leptospirosis, parvovirus, enterovirus, rubella, and secondary syphilis. 
Laboratory diagnosis
Due to the fact that currently no commercial tests allowing for the serological diagnosis of ZIKV infection are available, ZIKV acute infection may be diagnosed by RT-PCR (reverse transcription polymerase chain reaction) directly from virus RNA in patient's serum, preferably obtained up to the sixth day of disease. However, the virus was identified (by virus genomic amplification) at the 11th day upon symptom onset in- one patient from the epidemic on the island of Yap 43 .
The virus may also be detected by using molecular techniques in other body fluids like saliva and in urine 37 .
IgM antibodies may be found from the third day of disease onset and IgG antibodies should be looked for in the acute and convalescent serum 44 . The possible crossreactivity related to previous infections with other flaviviruses can be a problem 46 . The presence of ZIKV epidemics in regions where dengue virus was previously in circulation may represent a diagnostic challenge. Even the use of a plaque reduction neutralization test (PRNT), also used in the epidemic on the island of Yap, is unable to differentiate possible cases of ZIKV infection in patients with previously acquired antidengue virus antibodies, even when the anti-ZIKV titres were higher than the heterologous (non-ZIKV).
Nevertheless, different studies have described both qualitative and quantitative assessments regarding the presence of anti-ZIKV antibodies in biological samples where some of the techniques that have been used are non-standardized techniques used in specific laboratory contexts (in-house techniques). Despite the presence of diagnostic tests, its use is still rather limited as no commercial kits are available on the market. Therefore, diagnosis is restricted to public health, training and research institutions. The detection of viral genome through RT-PCR is the most sensitive and specific method for the diagnosis of the ZIKV infection; however, these are not fail-safe methods. Unlike other viruses, the limited circulation of the virus has reduced the knowledge regarding its real genetic diversity and therefore there is a non-zero probability that the primers used in ZIKV genomic amplification may not allow the required amplifications to be obtained (false-negative results in amplification tests).
Treatment
There is currently no vaccine against Zika virus, nor specific antiviral for the treatment of Zika virus. Treatment is symptomatic, although it is not known what agents are optimal for treating the fever, itch, and arthralgia. Minimisation of the chance of mosquito bites is advised by wearing long sleeves and trousers and using mosquito repellents 46 . Specific travel advice is dealt with in the accompanying article 47, 48 .
Control measures
Ae. aegypti is a highly synanthropic mosquito that takes advantage from peri-domestic environments and may even make its blood meals within human households. Considering that it is one of the ZIKV vectors and that vector control measures based on the use of insecticide agents are difficult due to (i) financial constraints, (ii) logistic issues, (iii) strict regulations regarding the use of insecticide agents and/or (iv) spreading of resistances in vector population, removal of larval breeding sites has a crucial role in the control of this vector. Individual protection measures should also be encouraged, involving the use of insect repellents and window and door screens to keep insects outside. The detection and study of suspected cases, aimed to prevent transmission in more problematic regions should be the priority in health surveillance. Those with an active disease or that recently presented with it are unable to donate blood.
Although no ZIKV-related deaths occurred until now, health professionals should be aware and trained in order to differentiate ZIKV disease from other diseases that simultaneously circulate, namely dengue 49 .
Attention to travellers returning from regions with ZIKV transmission should be a priority in ZIKV-free regions. Early recognition may contribute to take measures aimed to prevent disease spreading, considering the spread of Ae. albopictus in temperate regions.
Conclusion
ZIKV-related epidemics over the last decade lead to a relevant spreading from Asia and Pacific Ocean to the Americas. It is not yet known whether this flavivirus will establish within these new territories and further studies on its transmission dynamics are needed. Its presence in areas where the transmission of other flaviviruses has been already observed, such as the different serotypes of dengue virus, brings the possibility of an increase in mortality due to issues related to the differential diagnosis and also to the unavailability of commercial diagnostic kits. Despite the apparently benign characteristics of the disease, potentially lethal complications such as GBS emerged as a new issue in the approach to patients presenting in regions with active transmission. Vector control measures should be increased, as well as healthcare actions. In ZIKV-free regions and where there is the circulation of Aedes mosquitoes, care should be taken with travellers returning mainly from tropical regions.
